Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib in Recurrent or Progressive Low-Grade Serous Ovarian or Peritoneal Cancer
NCT02101788Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2014
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of trametinib in ovarian cancer, primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Started Apr 2014; status: completed.
02
Drugs
trametinib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02101788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02101788.